Kyntra Bio Slashes Royalty Obligations by $60M, Extends Cash Runway to Q4 2027
KYNB sits 21% above its 52-week low of $6.32.
Summary
Kyntra Bio restructured its royalty financing with NQ Project Phoebus, cutting maximum future payments from $125M to $65M via a $42.6M upfront payment. The deal reduces total liabilities by roughly $80M when combined with the FibroGen Europe bankruptcy settlement, and pro forma cash stands at $53.1M with runway into Q4 2027. This follows the Q2 10-Q that disclosed a Nasdaq delisting notice and a $30.9M bankruptcy gain, so the balance sheet cleanup is material for a company with a $31.5M market cap. The company also reiterated Phase 2 FG-3246 interim data expected in Q4 2026 and a pivotal roxadustat Phase 3 start in Q4 2026. The upfront payment consumes nearly half of reported cash, but the liability reduction and extended runway are net positives for solvency.
Updates
· SEC 8-K — The 8-K states the amended agreement eliminates all future true-up payments and releases Japan royalties from collateral; remaining $15M obligation is payable from 50% of Astellas revenue excluding Japan.
At the time of this announcement, KYNB was trading at $7.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.5M. The 52-week trading range was $6.32 to $12.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.